Enhancement on Japan PharmaPoint Migraine – Drug Market Forecast and Analysis to 2023


“The Report PharmaPoint: Migraine – Japan Drug Forecast and Market Analysis to 2023 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz”

The Migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and sideeffects profile.

The launch of drugs in the Japanese market is often delayed due to the requirement by Japanese regulatory agencies to perform clinical studies in Japanese patients; as a result, the market uptake of lasmiditan and MK1602 will occur at the very end of the forecast period, when they are expected to steal shares from triptans as well as gaining additional patient share from the underserved population.

Download Sample copy of this Report at : http://www.marketresearchreports.biz/sample/sample/195541


  • Overview of Migraine including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

  • Detailed information on the key drugs in the Japan including product description, safety and efficacy profiles as well as a SWOT analysis.

  • Sales forecast for the top drugs in the Japan from 20122023.

  • Analysis of the impact of key events as well the drivers and restraints affecting the Japan Migraine market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return

  • Stay ahead of the competition by understanding the changing competitive landscape for Migraine

  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

  • Make more informed business decisions from insightful and indepth analysis of drug performance

  • Obtain sales forecast for drugs from 20122023 in the Japan

Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports-biz

Table of Contents

1 Table of Contents 5

1.1 List of Tables 9

1.2 List of Figures 10

2 Introduction 11

2.1 Catalyst 11

2.2 Related Reports 12

2.3 Upcoming Related Reports 13

3 Disease Overview 14

3.1 Etiology and Pathophysiology 16

3.1.1 Etiology 16

3.1.2 Pathophysiology 17

3.1.3 Prognosis 18

3.2 Symptoms 18

3.2.1 Premonitory Phase 18

3.2.2 Aura Phase 19

3.2.3 Headache Phase 20

3.2.4 Postdrome Phase 20

4 Disease Management 21

4.1 Treatment Overview 21

4.1.1 Acute Migraine Treatment 24

4.1.2 Preventive Migraine Treatment 25

4.2 Japan 26

4.2.1 Diagnosis 26

4.2.2 Clinical Practice 26

5 Competitive Assessment 27

5.1 Overview 27

5.2 Strategic Competitor Assessment 28

5.3 Product Profiles- Major Brands 29

5.3.1 Triptans 29

5.3.2 Imitrex (sumatriptan) 31

5.3.3 Zomig (zolmitriptan) 33

5.3.4 Amerge (naratriptan) 35

5.3.5 Maxalt (rizatriptan) 36

5.3.6 Axert (almotriptan) 38

5.3.7 Frova (frovatriptan) 39

5.3.8 Relpax (eletriptan) 41

5.3.9 Ergot Alkaloids 42

5.3.10 Beta Blockers 47

5.3.11 Anti-Epileptics 50

5.3.12 Antidepressants 54

5.3.13 Calcium Channel Antagonists 56

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz